In HCC, artemisinin disrupts cellular bioenergetics and inactivates Hippo-YAP signaling [252], while artesunate exacerbates AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy and mitigates sorafenib resistance [78]. This evidence concerns the gene FUNDC1 and hepatocellular carcinoma.